Ovarian Cancer

Latest News

Ovarian cancer awareness | Image Credit: Queenmoonlite Studio - stock.adobe.com
Underuse of Maintenance Therapies Highlights Need for Improved Care Strategies in Advanced Ovarian Cancer

July 21st 2025

Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting care gaps.

3D ovarian cancer illustration | Image Credit: Lars Neumann - stock.adobe.com
Updated OVARIO Trial Results Reinforce Niraparib Plus Bevacizumab Maintenance for Advanced Ovarian Cancer

July 13th 2025

GLP-1 receptor agonists | Image Credit: K KStock - stock.adobe.com
GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer

July 11th 2025

US map | Image Credit: iiierlok_xolms - stock.adobe.com
Disparities Persist Despite Declining US Ovarian Cancer Death Rates

July 9th 2025

Ovarian cancer | Image Credit: tashatuvango - stock.adobe.com
Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

June 27th 2025

Advancing Ovarian Cancer Treatment: Insights From Emerging Therapies

Discover how advancements in BRCA, folate receptor alpha, HER2, and CCNE1 testing are shaping ovarian cancer care while addressing barriers in education, access, and tumor diversity.

AJMC Insights logo displayed over a dark blue abstract background with flowing wave-like patterns.
Continuing Medical Education
View All
August 1st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 1st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Phase 1 Study of Novel Drug for Ovarian Cancer Shows Positive Results
December 5th 2020

Phase 1 Study of Novel Drug for Ovarian Cancer Shows Positive Results

AJMC Staff
One patient had a complete response and the majority of patients achieved disease control at 12 weeks.
Discussion of Ovarian Cancer Risk
December 4th 2020

Assisted Reproductive Technology Does Not Increase Ovarian Cancer Risk

Rose McNulty
New findings in Journal of the National Cancer Institute contradict previous research indicating that assisted reproductive technology might lead to an increased risk of ovarian cancer.
Study Examines Impact of Tumor Mutational Burden on Ovarian Cancer
November 25th 2020

Study Examines Impact of Tumor Mutational Burden on Ovarian Cancer

Allison Inserro
Tumor mutational burden is an emerging biomarker to predict response to immune checkpoint inhibitors, but its utility as a prognostic indicator in ovarian cancer is unclear.
Small Study Finds Potential Risk of Hematologic Abnormalities After Ovarian Cancer Treatment
November 24th 2020

Small Study Finds Potential Risk of Hematologic Abnormalities After Ovarian Cancer Treatment

Jared Kaltwasser
The new report suggests that patients treated with prolonged poly-ADP-ribose polymerase inhibitors after chemotherapy may need close hematological monitoring.
Patients With Ovarian Cancer Struggle With Uncertainty, Fears of Future, Study Finds
November 23rd 2020

Patients With Ovarian Cancer Struggle With Uncertainty, Fears of Future, Study Finds

Jared Kaltwasser
The dearth of effective treatment options for patients with ovarian cancer not only leads to poor health outcomes, but also leads to psychological distress, according to new research.
Ovarian tumor graphic
November 19th 2020

Review Offers First Head-to-Head Look at PARP Inhibitors for Ovarian Cancer

Jaime Rosenberg
Drawing on data from 6 randomized controlled trials accounting for over 2200 patients, the researchers the researchers compared the efficacy and safety of olaparib, rucaparib, and niraparib.
Careful Observation of Ovarian Cysts Safe Alternative to Surgery
February 9th 2019

Careful Observation of Ovarian Cysts Safe Alternative to Surgery

Samantha DiGrande
Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.
Dr John Schorge Discusses Prevention Methods in Ovarian Cancer
June 30th 2018

Dr John Schorge Discusses Prevention Methods in Ovarian Cancer

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses different prevention methods in ovarian cancer.
Site Logo
August 18th 2017

Expanded Approval, New Dosage Form for Olaparib in Recurrent Ovarian Cancer

Surabhi Dangi-Garimella, PhD
A new oral dosage form of olaparib (Lynparza) has been approved as maintenance treatment in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
<1
...
34567

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo